Mechanistic Principles of Antisense Targets for the Treatment of Spinal Muscular Atrophy

References

• Prior TW . Spinal muscular atrophy diagnostics. J. Child Neurol.22 (8), 952–956 (2007).
   PubMed Web of Science ®Google Scholar
• Kolb SJ , KisselJT. Spinal muscular atrophy: a timely review. Arch. Neurol.68 (8), 979–984 (2011).
   PubMedGoogle Scholar
• Tiziano FD , MelkiJ, SimardLR. Solving the puzzle of spinal muscular atrophy: what are the missing pieces?Am. J. Med. Genet. A161A (11), 2836–2845 (2013).
   PubMedGoogle Scholar
• Nurputra DK , LaiPS, HarahapNIFet al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann. Hum. Genet.77 (5), 435–463 (2013).
   PubMed Web of Science ®Google Scholar
• Lefebvre S , BürglenL, ReboulletSet al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell80 (1), 155–165 (1995).
   PubMed Web of Science ®Google Scholar
• McAndrew PE , ParsonsDW, SimardLRet al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet.60 (6), 1411–1422 (1997).
   PubMed Web of Science ®Google Scholar
• Howell MD , SinghNN and SinghRN (2014). Advances in therapeutic development for spinal muscular atrophy. Fut. Med. Chem.9, 1081–1099 (2014).
   Google Scholar
• Lorson CL , HahnenE, AndrophyEJ, WirthB. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA96 (11), 6307–6311 (1999).
   PubMed Web of Science ®Google Scholar
• Lorson CL , StrasswimmerJ, YaoJMet al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet.19 (1), 63–66 (1998).
   PubMed Web of Science ®Google Scholar
• Le TT , PhamLT, ButchbachMEet al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet.14 (6), 845–857 (2005).
   PubMed Web of Science ®Google Scholar
• Burnett BG , MuñozE, TandonA, KwonDY, SumnerCJ, FischbeckKH. Regulation of SMN protein stability. Mol. Cell. Biol.29 (5), 1107–1115 (2009).
   PubMed Web of Science ®Google Scholar
• Cho S , DreyfussG. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev.24 (5), 438–442 (2010).
   PubMed Web of Science ®Google Scholar
• Feldkotter M , SchwarzerV, WirthR, WienkerTF, WirthB. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet.70 (2), 358–368 (2002)
   PubMed Web of Science ®Google Scholar
• Parsons DW , McAndrewPE, IannacconeST, MendellJR, BurghesAH, PriorTW. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am. J. Hum. Genet.63 (6), 1712–1723 (1998).
   PubMed Web of Science ®Google Scholar
• Wirth B , BrichtaL, SchrankBet al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet.119 (4), 422–428 (2006).
   PubMed Web of Science ®Google Scholar
• Tiziano FD , BertiniE, MessinaSet al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul. Disord.17 (5), 400–403 (2007).
   PubMed Web of Science ®Google Scholar
• Schrank B , GötzR, GunnersenJMet al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA94 (18), 9920–9925 (1997).
   PubMed Web of Science ®Google Scholar
• Hammond SM , GogliottiRG, RaoV, BeauvaisA, KotharyR, DiDonatoCJ. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS ONE5 (12), e15887 (2010).
   PubMed Web of Science ®Google Scholar
• Park GH , KariyaS, MonaniUR. Spinal muscular atrophy: new and emerging insights from model mice. Curr. Neurol. Neurosci. Rep.10 (2), 108–117 (2010).
   PubMed Web of Science ®Google Scholar
• Sleigh JN , GillingwaterTH, TalbotK. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis. Model Mech.4 (4), 457–467 (2011).
   PubMed Web of Science ®Google Scholar
• Bebee TW , DominguezCE, ChandlerDS. Mouse models of SMA: tools for disease characterization and therapeutic development. Hum. Genet.131 (8), 1277–1293 (2012).
   PubMed Web of Science ®Google Scholar
• Kariya S , ParkGH, Maeno-HikichiYet al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet.17 (16), 2552–2569 (2008).
   PubMed Web of Science ®Google Scholar
• Murray LM , ComleyLH, ThomsonD, ParkinsonN, TalbotK, GillingwaterTH. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet.17 (7), 949–962 (2008).
   PubMed Web of Science ®Google Scholar
• Kong L , WangX, ChoeDWet al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci.29 (3), 842–851 (2009).
   PubMed Web of Science ®Google Scholar
• Ling KK , LinMY, ZinggB, FengZ, KoCP. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS ONE5 (11), e15457 (2010).
   PubMed Web of Science ®Google Scholar
• Ruiz R , CasanasJJ, Torres-BenitoL, CanoR, TabaresL. Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. J. Neurosci.30 (3), 849–57 (2010).
   PubMed Web of Science ®Google Scholar
• Lee YI , MikeshM, SmithI, RimerM, ThompsonW. Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev. Biol.356 (2), 432–444 (2011).
   PubMed Web of Science ®Google Scholar
• Mentis GZ , BlivisD, LiuWet al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron69 (3), 453–467 (2011).
   PubMed Web of Science ®Google Scholar
• Dachs E , HereuM, PiedrafitaL, CasanovasA, CalderóJ, EsquerdaJE. Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal muscular atrophy. J. Neuropathol. Exp. Neurol.70 (6), 444–461 (2011).
   PubMed Web of Science ®Google Scholar
• Gogliotti RG , QuinlanKA, BarlowCB, HeierCR, HeckmanCJ, DidonatoCJ. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory–motor defects are a consequence, not a cause, of motor neuron dysfunction. J. Neuro.32 (11), 3818–29 (2012).
   Google Scholar
• Bevan AK , HutchinsonKR, FoustKDet al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet.19 (20), 3895–3905 (2010).
   PubMed Web of Science ®Google Scholar
• Heier CR , SattaR, LutzC, DiDonatoCJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet.19 (20), 3906–3918 (2010).
   PubMed Web of Science ®Google Scholar
• Shababi M , HabibiJ, YangHT, ValeSM, SewellWA, LorsonCL. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet.19 (20), 4059–4071 (2010).
   PubMed Web of Science ®Google Scholar
• Schreml J , RiesslandM, PaternoMet al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur. J. Hum. Genet.21 (6), 643–652 (2013).
   PubMed Web of Science ®Google Scholar
• Bowerman M , SwobodaKJ, MichalskiJ-Pet al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann. Neurol.72 (2), 256–268 (2012).
   PubMed Web of Science ®Google Scholar
• Shababi M , LorsonCL, Rudnik-SchönebornSS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?J. Anat.224 (1), 15–28 (2014).
   PubMed Web of Science ®Google Scholar
• Kernochan LE , RussoML, WoodlingNSet al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet.14 (9), 1171–1182.
   PubMed Web of Science ®Google Scholar
• Farooq F , BalabanianS, LiuX, HolcikM, MacKenzieA. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum. Mol. Genet.18 (21), 4035–4045 (2009).
   PubMed Web of Science ®Google Scholar
• Farooq F , MolinaFA, HadwenJet al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J. Clin. Invest.121 (8), 3042–3050 (2011).
   PubMed Web of Science ®Google Scholar
• Kwon DY , MotleyWW, FischbeckKH, BurnettBG. Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Hum. Mol. Genet.20 (18), 3667–77 (2011).
   PubMed Web of Science ®Google Scholar
• Singh NN , SeoJ, OttesenEW, ShishimorovaM, BhattacharyaD, SinghRN. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol. Cell. Biol.31 (5), 935–954 (2011).
   PubMed Web of Science ®Google Scholar
• Xiao J , MaruganJJ, ZhengWet al. Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J. Med. Chem.54 (18), 6215–6233 (2011).
   PubMed Web of Science ®Google Scholar
• Hsu YY , JongYJ, TsaiHH, TsengYT, AnLM, LoYC. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice. Br. J. Pharmacol.166 (3), 1114–26 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou J , TawkM, TizianoFDet al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am. J. Hum. Genet.91 (1), 5–14 (2015).
   Google Scholar
• Oprea GE , KröberS, McWhorterMLet al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science320 (5875), 524–527 (2008).
   PubMed Web of Science ®Google Scholar
• Bebee TW , DominguezCE, Samadzadeh-TarighatS, AkehurstKL, ChandlerDS. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model. Hum. Mol. Genet.21 (19), 4301–4313 (2012).
   PubMed Web of Science ®Google Scholar
• Singh NN , SeoJ, RahnS and SinghRN. A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes. PLoS ONE7 (11), e49595 (2012).
   PubMed Web of Science ®Google Scholar
• Naryshkin NA , WeetallM, DakkaAet al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science345 (6197), 688–693 (2014).
   PubMed Web of Science ®Google Scholar
• Rigo F , HuaY, KrainerAR, BennettCF. Antisense-based therapy for the treatment of spinal muscular atrophy. J. Cell Biol.199 (1), 21–25 (2012).
   PubMed Web of Science ®Google Scholar
• Porensky PN , BurghesAH. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum. Gene. Ther.24 (5), 489–498 (2013).
   PubMed Web of Science ®Google Scholar
• Arnold WD , BurghesAH. Spinal muscular atrophy: development and implementation of potential treatments. Ann. Neurol.74 (3), 348–62 (2013).
   PubMed Web of Science ®Google Scholar
• Seo J , HowellMD, SinghNN and SinghRN (2013). Spinal muscular atrophy: An update on therapeutic progress. Biochim. Biophys. Acta.1832 (12), 2180–2190 (2013).
   PubMed Web of Science ®Google Scholar
• Singh P , LiewWK, DarrasBT. Current advances in drug development in spinal muscular atrophy. Curr. Opin. Pediatr.25 (6), 682–688 (2013).
   PubMed Web of Science ®Google Scholar
• Awano T , KimJ-K, MonaniUR. Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics11 (4), 786–795 (2014).
   PubMed Web of Science ®Google Scholar
• d'Ydewalle C , SumnerCJ. Spinal muscular atrophy therapeutics: where do we stand?Neurotherapeutics12 (2), 303–316 (2015).
   PubMed Web of Science ®Google Scholar
• Lim SR , HertelKJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J. Biol. Chem.276 (48), 45476–45483 (2001).
   PubMed Web of Science ®Google Scholar
• Miyajima H , MiyasoH, OkumuraM, KurisuJ, ImaizumiK. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J. Biol. Chem.277 (26), 23271–77 (2002).
   PubMed Web of Science ®Google Scholar
• Singh NK , SinghNN, AndrophyEJ, SinghRN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol.26 (4), 1333–1346 (2006).
   PubMed Web of Science ®Google Scholar
• Singh NN , ShishimorovaM, CaoLC, GangwaniL, SinghRN. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol.6 (3), 341–350 (2009).
   PubMed Web of Science ®Google Scholar
• Singh NN , LawlerMN, OttesenEW, UpretiD, KaczynskiJR, SinghRN. An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucl. Acids Res.41 (17), 8144–8165 (2013).
   PubMed Web of Science ®Google Scholar
• Pao PW , WeeKB, YeeWC, PramonoZA. Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Mol. Ther.22 (4), 854–61 (2014).
   PubMed Web of Science ®Google Scholar
• Sivanesan S , HowellMD, DiDonatoCJ, SinghRN. Antisense oligonucleotide mediated therapy of spinal muscular atrophy. Transl. Neurosc.4 (1), 1–7 (2013).
   Web of Science ®Google Scholar
• ClinicalTrials Database : NCT02193074. https://clinicaltrials.gov/ct2/show/NCT02193074.
   Google Scholar
• Muntoni F , WoodMJ. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug. Discov.10 (8), 621–637 (2011).
   PubMed Web of Science ®Google Scholar
• Kole R , KrainerAR, AltmanS. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug. Discov.11 (2), 125–140 (2012).
   PubMed Web of Science ®Google Scholar
• Havens MA , DuelliDM, HastingsML. Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev. RNA4 (3), 247–266 (2013).
   PubMed Web of Science ®Google Scholar
• Singh NN and SinghRN. Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. RNA Biol.8 (4), 600–606 (2011).
   PubMed Web of Science ®Google Scholar
• Kashima T , RaoN, ManleyJL. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc. Natl Acad. Sci. USA104 (9), 3426–3231 (2007).
   PubMed Web of Science ®Google Scholar
• Singh NN , SinghRN, AndrophyEJ. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res.35 (2), 371–389 (2007).
   PubMed Web of Science ®Google Scholar
• Singh NN , AndrophyEJ, SinghRN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA10 (8), 1291–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Cartegni L , KrainerAR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol.10 (2), 120–5 (2003).
   PubMedGoogle Scholar
• Skordis LA , DunckleyMG, YueB, EperonIC, MuntoniF. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl Acad. Sci. USA100 (7), 4114–4119 (2003).
   PubMed Web of Science ®Google Scholar
• Singh NN , AndrophyEJ, SinghRN. An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem. Biophys. Res. Commun.315 (2), 381–388 (2004).
   PubMed Web of Science ®Google Scholar
• Singh NN , AndrophyEJ, SinghRN. The regulation and regulatory activities of alternative splicing of the SMN gene. Crit. Rev. Eukaryot. Gene Expr.14 (4), 271–285 (2004).
   PubMed Web of Science ®Google Scholar
• Mende Y , JakubikM, RiesslandMet al. Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing. Hum. Mol. Genet.19 (11), 2154–2167 (2010).
   PubMed Web of Science ®Google Scholar
• Xiong HY , AlipanahiB, LeeLJet al. The human splicing code reveals new insights into the genetic determinants of disease. Science347 (6218), 1254806 (2015).
   PubMed Web of Science ®Google Scholar
• Burge CB , TuschlT, SharpPA. Splicing of precursors to mRNAs by the spliceosomes. In : The RNA World (2nd Ed). GestelandRFet al.Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 525–560 (1999).
   Google Scholar
• Buratti E , BaralleF. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol. Cell. Biol.24 (24), 10505–10514 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez-Contreras R , FisetteJF, NasimFU, MaddenR, CordeauM, ChabotB. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol.4 (2), e21 (2006).
   PubMed Web of Science ®Google Scholar
• Shepard PJ , HertelKJ. Conserved RNA secondary structures promote alternative splicing. RNA14 (8), 1463–1469 (2008).
   PubMed Web of Science ®Google Scholar
• Warf MB , BerglundJA. Role of RNA structure in regulating pre-mRNA splicing. Trends Biochem. Sci.35 (3), 169–178 (2010).
   PubMed Web of Science ®Google Scholar
• Hua Y , VickersTA, BakerBF, BennettCF, KrainerAR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol.5 (4), e73 (2007).
   PubMed Web of Science ®Google Scholar
• Hua Y , VickersTA, OkunolaHL, BennettCF, KrainerAR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet.82 (4), 834–848 (2008).
   PubMed Web of Science ®Google Scholar
• Geary RS , BakerBF, CrookeST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet.54 (2), 133–146 (2015).
   PubMed Web of Science ®Google Scholar
• Hua Y , SahashiK, RigoFet al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature478 (7367), 123–126 (2011).
   PubMed Web of Science ®Google Scholar
• Porensky PN , MitrpantC, McGovernVLet al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet.21 (7), 1625–1638 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou H , JanghraN, MitrpantCet al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther.24 (3), 331–342 (2013).
   PubMed Web of Science ®Google Scholar
• Mitrpant C , PorenskyP, ZhouHet al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLOS ONE8 (4), e62114 (2013).
   PubMed Web of Science ®Google Scholar
• Nizzardo M , SimoneC, SalaniSet al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Clin. Ther.36 (3), 340–56. e5 (2014).
   PubMed Web of Science ®Google Scholar
• Singh NN , HollingerK, BhattacharyaD, SinghRN. An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing. RNA16 (6), 1167–81 (2010).
   PubMed Web of Science ®Google Scholar
• Singh NN , SeoJ, OttesenEW, ShishimorovaM, BhattacharyaD, SinghRN. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol. Cell. Biol.31 (5), 935–954 (2011).
   PubMed Web of Science ®Google Scholar
• Singh NN , LeeBM, SinghRN. Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions. Ann. NY Acad. Sci.1341, 176–187 (2015).
   PubMed Web of Science ®Google Scholar
• Cheng CY , ChouF-C, DasR. Modeling complex RNA tertiary folds with Rosetta. Methods Enzymol.553, 35–64 (2015).
   PubMed Web of Science ®Google Scholar
• Keil JM , SeoJ, HowellMD, HsuWH, SinghRN, DiDonatoCJ. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol. Ther. Nucl. Acids.3, e174 (2014).
   Google Scholar
• Osman EY , MillerMR, RobbinsKLet al. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum. Mol. Genet.23 (18), 4832–4845 (2014).
   PubMed Web of Science ®Google Scholar
• Salmena L , PolisenoL, TayY, KatsL, PandolfiPP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?Cell146 (3), 353–358 (2011).
   PubMed Web of Science ®Google Scholar
• Madocsai C , LimSR, GeibT, LamBJ, HertelKJ. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol. Ther.12 (6), 1013–1022 (2005).
   PubMed Web of Science ®Google Scholar
• Geib T , HertelKJ. Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS ONE4 (12), e8204 (2009).
   PubMed Web of Science ®Google Scholar
• Owen N , ZhouH, MalyginAAet al. Design principles for bifunctional targeted oligonucleotide enhancers of splicing. Nucl. Acids Res.39 (16), 7194–7208 (2011).
   PubMed Web of Science ®Google Scholar
• Smith LD , DickinsonRL, LucasCMet al. A targeted oligonucleotide enhancer of SMN2 exon 7 splicing forms competing quadruplex and protein complexes in functional conditions. Cell Rep.9 (1), 193–205 (2014).
   PubMed Web of Science ®Google Scholar
• Marquis J , MeyerK, AngehrnL, KämpferSS, Rothen-RutishauserB, SchümperliD. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. Ther.15 (8), 1479–86 (2007).
   PubMed Web of Science ®Google Scholar
• Meyer K , MarquisJ, TrübJet al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet.18 (3), 546–555 (2009).
   PubMed Web of Science ®Google Scholar
• Voigt T , MeyerK, BaumO, SchümperliD. Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for spinal muscular atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. Neuromuscul. Disord.20 (11), 744–52 (2010).
   PubMed Web of Science ®Google Scholar
• Baughan T , ShababiM, CoadyTH, DicksonAM, TullisGE, LorsonCL. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther.14 (1), 54–62 (2006).
   PubMed Web of Science ®Google Scholar
• Dickson A , OsmanE, LorsonCL. A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene Ther.19 (11), 1307–1315 (2008).
   PubMed Web of Science ®Google Scholar
• Baughan TD , DicksonA, OsmanEY, LorsonCL. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet.18 (9), 1600–1611 (2009).
   PubMed Web of Science ®Google Scholar
• Osman EY , YenPF, LorsonCL. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol. Ther.20 (1), 119–126 (2012).
   PubMed Web of Science ®Google Scholar
• Landis SC , AmaraSG, AsadullahKet al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature490 (7419), 187–191 (2012).
   PubMed Web of Science ®Google Scholar
• Haibe-Kains B , El-HachemN, BirkbakNJet al. Inconsistency in large pharmacogenomic studies. Nature504 (7480), 389–393 (2013).
   PubMed Web of Science ®Google Scholar
• Perrin S . Preclinical research: make mouse studies work. Nature507 (7493), 423–425 (2014).
   PubMed Web of Science ®Google Scholar